Pristin-ol
Generic Name
Olmesartan Medoxomil
Manufacturer
Example Pharma Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| pristin ol 5 mg tablet | ৳ 5.02 | N/A |
Description
Overview of the medicine
Pristin-ol 5 mg Tablet contains Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily.
Uses & Indications
Dosage
Adults
The usual starting dose is 20 mg once daily. For patients requiring further blood pressure reduction, the dose may be increased to 40 mg once daily. Pristin-ol 5 mg is suitable for initial treatment or dose titration.
Elderly
No initial dosage adjustment is usually necessary for elderly patients, but caution should be exercised.
Renal_impairment
In patients with mild to moderate renal impairment, no initial dosage adjustment is recommended. For severe renal impairment, a lower starting dose (e.g., 10 mg once daily) may be considered, and careful monitoring is advised.
How to Take
Pristin-ol tablets should be swallowed whole with water, with or without food, at approximately the same time each day.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to olmesartan, which selectively blocks the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to vasodilation and reduced blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect begins within 1-2 hours; maximum reduction in blood pressure generally achieved within 2 weeks of starting therapy.
Excretion
Approximately 50-65% is excreted via the liver (biliary) and 35-50% via the kidneys (renal) as unchanged drug.
Half life
Approximately 13 hours.
Absorption
Rapidly absorbed from the gastrointestinal tract and completely converted to olmesartan during absorption. Bioavailability is approximately 26%. Peak plasma concentration is reached within 1-2 hours.
Metabolism
The medoxomil moiety is completely hydrolyzed to olmesartan in the GI tract. Olmesartan is not significantly metabolized by the cytochrome P450 system.
Side Effects
Contraindications
- Hypersensitivity to olmesartan or any excipients.
- Second and third trimesters of pregnancy.
- Biliary obstruction.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
Drug Interactions
Lithium
Concurrent use may lead to increased serum lithium concentrations and toxicity. Monitor lithium levels carefully.
Other antihypertensive agents
Additive hypotensive effect may occur.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Potassium-sparing diuretics & Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension (low blood pressure) and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive, including monitoring vital signs and cardiovascular status. If ingestion is recent, gastric lavage may be considered.
Pregnancy & Lactation
Pristin-ol is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. It is not recommended during the first trimester. It is unknown whether olmesartan is excreted in human milk, so caution is advised, and breastfeeding is generally not recommended.
Side Effects
Contraindications
- Hypersensitivity to olmesartan or any excipients.
- Second and third trimesters of pregnancy.
- Biliary obstruction.
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
Drug Interactions
Lithium
Concurrent use may lead to increased serum lithium concentrations and toxicity. Monitor lithium levels carefully.
Other antihypertensive agents
Additive hypotensive effect may occur.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
May reduce the antihypertensive effect and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Potassium-sparing diuretics & Potassium supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
The most likely manifestation of overdose is hypotension (low blood pressure) and possibly tachycardia; bradycardia could occur from parasympathetic stimulation. Treatment is symptomatic and supportive, including monitoring vital signs and cardiovascular status. If ingestion is recent, gastric lavage may be considered.
Pregnancy & Lactation
Pristin-ol is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. It is not recommended during the first trimester. It is unknown whether olmesartan is excreted in human milk, so caution is advised, and breastfeeding is generally not recommended.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months (2 years) from manufacturing date
Availability
Available in pharmacies and hospitals
Approval Status
Approved by regulatory authorities
Patent Status
Patent expired in many regions, generics available
Clinical Trials
Olmesartan Medoxomil has undergone extensive clinical trials demonstrating its efficacy and safety in the treatment of hypertension, including trials comparing it to other antihypertensive agents.
Lab Monitoring
- Regular monitoring of blood pressure.
- Monitoring of renal function (serum creatinine, BUN).
- Monitoring of serum electrolyte levels (especially potassium).
Doctor Notes
- Careful monitoring of blood pressure, renal function, and serum potassium levels is crucial, especially when initiating therapy or increasing dosage.
- Use with caution in patients with volume depletion or severe congestive heart failure, as symptomatic hypotension may occur.
- Avoid concomitant use with NSAIDs in patients at risk of renal impairment.
Patient Guidelines
- Take the medicine regularly as prescribed by your doctor, even if you feel well.
- Do not stop taking Pristin-ol suddenly without consulting your doctor.
- Inform your doctor about all other medications you are taking, including over-the-counter drugs and herbal supplements.
- Avoid potassium supplements or salt substitutes containing potassium without medical advice.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Pristin-ol may cause dizziness or lightheadedness, especially at the start of treatment or when changing doses. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain a low-sodium diet.
- Engage in regular physical activity.
- Avoid smoking and limit alcohol consumption.
- Manage stress and maintain a healthy weight.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.